Low‐dose isotretinoin for the management of rosacea: A systematic review and meta‐analysis
Journal of the European Academy of Dermatology and Venereology · 2025-04 · 39 (4) · 785-792
DOI: 10.1111/jdv.20315 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 06.09.2024. Verfasst von Aliyah King und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Dermatologic Agents, Isotretinoin, Rosacea. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Rosacea is a chronic, relapsing inflammatory dermatosis predominantly affecting the central face and can result in significant psychosocial impacts. Isotretinoin has been studied for rosacea due to its anti‐inflammatory and sebum reduction properties, but its use remains limited likely due to its off‐label use and potential adverse events.
Objective
This systematic review and meta‐analysis investigated the efficacy and safety of low‐dose isotretinoin (LDI; ≤0.5 mg/kg/day) for the four main types of rosacea: erythematotelangiectatic, papulopustular, phymatous and ocular rosacea.
Methods
Randomized and non‐randomized studies evaluating LDI for rosacea were included. Incomplete studies, non‐English studies and case reports were excluded. Study quality was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation scale.
Results
Of 435 studies, and 16 studies involving 1445 patients were included. LDI decreased lesion count ( p = 0.03) and erythema ( p = 0.01) with large effect [standardized mean difference (SMD) > 0.8]. Compared to topical retinoids and topical antimicrobials, isotretinoin had larger reductions in lesion count ( p = 0.03) with moderate effect (SMD > 0.5). Mean lesion count and erythema remained reduced by 70% and 47%, respectively, at 16 weeks after LDI cessation. Relapse rate was 35% at 5.5 months post‐isotretinoin, and three patients (0.4%) experienced worsening of rosacea. Three patients (0.4%) experienced serious adverse events.
Conclusions
Study design heterogeneity limited more comprehensive comparisons. Overall, low‐dose isotretinoin may serve as an effective treatment for rosacea with good tolerability and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
- Division of Dermatology, University of Ottawa, Ottawa, Ontario, Canada.
- Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Epiphany Dermatology, Dallas, Texas, USA.
- Baylor University Medical Center, Dallas, Texas, USA.
- Department of Dermatology, University of Texas at Southwestern, Dallas, Texas, USA.
ORCID-Profile: Aliyah King, Marcus G Tan, Stanislav N Tolkachjov
Zitieren
APA
King, A., Tan, M. G., Kirshen, C., & Tolkachjov, S. N. (2025). Low‐dose isotretinoin for the management of rosacea: A systematic review and meta‐analysis. Journal of the European Academy of Dermatology and Venereology, 39(4), 785-792. https://doi.org/10.1111/jdv.20315
Vancouver
King A, Tan MG, Kirshen C, Tolkachjov SN. Low‐dose isotretinoin for the management of rosacea: A systematic review and meta‐analysis. Journal of the European Academy of Dermatology and Venereology. 2025;39(4):785-792. doi:10.1111/jdv.20315
BibTeX
@article{King2025,
author = {King, Aliyah and Tan, Marcus G and Kirshen, Carly and Tolkachjov, Stanislav N},
title = {Low‐dose isotretinoin for the management of rosacea: A systematic review and meta‐analysis},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2025},
volume = {39},
number = {4},
pages = {785--792},
doi = {10.1111/jdv.20315}
}
EUVIMED